$253.40+1.17%Close 13 Nov 2026 · Market value $37.52B
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
Biogen is valued at $37.52B on its latest close. Its price is 108.0 times its earnings.
| Market value | $37.52B |
|---|
| Enterprise value | $43.56B |
|---|
| Price / earnings | 107.98 |
|---|
| Price / sales | 3.64 |
|---|
| Price / book | 1.98 |
|---|
| EV / EBITDA | 26.68 |
|---|
| EV / sales | 4.23 |
|---|
| Price / free cash flow | 18.12 |
|---|
| Price / free cash flow, own 5-year average | 17.64 |
|---|
| EV / EBIT | 58.11 |
|---|
| EV / free cash flow | 21.07 |
|---|
| Free cash flow yield | 5.5% |
|---|
Share price
| Latest close | $253.40 |
|---|
| Day's change | +1.2% |
|---|
| 52-week high | $261.00 |
|---|
| 52-week low | $160.36 |
|---|
| From 52-week high | −2.9% |
|---|
| Return · 1 month | +8.9% |
|---|
| Return · 3 months | +18.2% |
|---|
| Return · year to date | +44.0% |
|---|
| Return · 1 year | +56.9% |
|---|
| Beta · 1 year against the S&P 500 | 0.37 |
|---|
| 50-day average | $233.35 |
|---|
| 200-day average | $205.15 |
|---|
| RSI 14 | 59.1 |
|---|
| Average volume · 20 sessions | 1.2M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 75.7% |
|---|
| Operating margin | 18.8% |
|---|
| Net margin | 13.1% |
|---|
| Free cash flow margin | 20.7% |
|---|
| Return on equity | 7.4% |
|---|
| Return on assets | 5.4% |
|---|
| Return on invested capital | 6.9% |
|---|
| Return on invested capital, 5-year average | 11.5% |
|---|
| Return on capital employed | 7.7% |
|---|
| Stock-based compensation / revenue | 2.9% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $3.01B |
|---|
| Total debt | $6.66B |
|---|
| Net debt | $2.84B |
|---|
| Current ratio | 2.68 |
|---|
| Quick ratio | 0.33 |
|---|
| Debt / equity | 0.36 |
|---|
| Net debt / EBITDA | 1.08 |
|---|
| Interest coverage | 6.96 |
|---|
Growth
| Revenue, latest quarter on a year | +10.6% |
|---|
| Revenue, twelve months on a year | +2.3% |
|---|
| EPS, latest quarter on a year | −104% |
|---|
| EPS, twelve months on a year | −78.7% |
|---|
| Revenue, 5-year compound | −6.0% |
|---|
| Revenue, 10-year compound | −0.8% |
|---|
| Net income, 5-year compound | −20.2% |
|---|
| Free cash flow, 5-year compound | −11.6% |
|---|
| EPS, 5-year compound | −18.7% |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 147M |
|---|
| Shares outstanding, 5-year compound | −1.8% |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $263.6M |
|---|
| Effective tax rate | 16.9% |
|---|
BIIB in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.